ABEO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.40%

Insider Buying (Last 12 Months): $154,047.12

Insider Selling (Last 12 Months): $36,199.24

Abeona Therapeutics Insider Trading History Chart

Abeona Therapeutics Share Price & Price History

^$5.70

▲ +0.07 (1.24%)

As of 12/20/2024 06:15 PM ET

Days: 30 | 90 | 365

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Abeona Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2024	Leila Alland	Director	Buy	11,000	$4.71	$51,810.00	82,857
4/26/2024	Faith L Charles	Director	Buy	7,550	$3.28	$24,764.00	78,323
4/25/2024	Brendan M. O'Malley	SVP	Buy	8,600	$3.24	$27,864.00	188,718
4/25/2024	Joseph Walter Vazzano	CFO	Buy	5,608	$3.14	$17,609.12	233,868
4/25/2024	Vishwas Seshadri	CEO	Buy	10,000	$3.20	$32,000.00	538,260
1/17/2024	Mark Alvino	Director	Sell	7,084	$5.11	$36,199.24	62,816
9/27/2023	Christine Berni Silverstein	Director	Sell	6,330	$3.91	$24,750.30	87,884
9/27/2023	Vishwas Seshadri	CEO	Buy	20,000	$4.07	$81,400.00	521,731
9/20/2023	Michael Amoroso	Director	Sell	327	$3.90	$1,275.30	114,465
9/18/2023	Brendan M. O'Malley	SVP	Buy	3,000	$3.80	$11,400.00	187,421
6/20/2023	Michael Amoroso	Director	Sell	338	$4.45	$1,504.10	114,792
3/20/2023	Michael Amoroso	Director	Sell	268	$2.33	$624.44	56,441
3/3/2023	Michael Amoroso	Director	Sell	1,002	$2.38	$2,384.76	56,709
12/9/2022	Brendan M. O'Malley	SVP	Buy	5,869	$3.13	$18,369.97	93,830
11/18/2022	Brendan M. O'Malley	SVP	Buy	7,500	$3.99	$29,925.00	87,961
11/18/2022	Joseph Walter Vazzano	CFO	Buy	2,500	$4.00	$10,000.00	95,250
6/6/2022	Mark Alvino	Director	Sell	35,000	$0.16	$5,600.00	47,181

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

SEC Filings (Institutional Ownership Changes) for Abeona Therapeutics (NASDAQ:ABEO)

80.56% of Abeona Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Abeona Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	55,000	$0.35M	0.0%	-28.0%	0.127%
11/16/2024	Geode Capital Management LLC	465,317	$2.94M	0.0%	+21.7%	1.074%
11/15/2024	Barclays PLC	55,000	$0.35M	0.0%	-28.0%	0.127%
11/15/2024	XTX Topco Ltd	25,301	$0.16M	0.0%	N/A	0.058%
11/15/2024	Jane Street Group LLC	13,216	$84K	0.0%	N/A	0.031%
11/15/2024	Western Standard LLC	1,698,097	$10.73M	10.1%	+7.0%	3.921%
11/15/2024	State Street Corp	159,295	$1.01M	0.0%	-1.6%	0.368%
11/15/2024	Ikarian Capital LLC	583,593	$3.69M	0.5%	-24.1%	1.347%
11/14/2024	Walleye Capital LLC	861,301	$5.44M	0.0%	-13.0%	1.989%
11/13/2024	Propel Bio Management LLC	624,022	$3.94M	2.3%	-50.0%	1.441%
11/12/2024	Citigroup Inc.	616,668	$3.90M	0.0%	+10.1%	1.424%
11/12/2024	Charles Schwab Investment Management Inc.	23,850	$0.15M	0.0%	N/A	0.055%
11/5/2024	GSA Capital Partners LLP	96,092	$0.61M	0.0%	+54.3%	0.222%
10/30/2024	Rosalind Advisors Inc.	1,832,000	$11.58M	7.3%	+4.7%	4.472%
10/25/2024	abrdn plc	326,995	$2.07M	0.0%	+158.8%	0.798%
8/13/2024	Simplify Asset Management Inc.	408,584	$1.73M	0.1%	N/A	0.997%
8/9/2024	Renaissance Technologies LLC	503,293	$2.13M	0.0%	+581.6%	1.229%
7/26/2024	Bank of New York Mellon Corp	121,453	$0.52M	0.0%	+2.0%	0.297%
7/12/2024	Rosalind Advisors Inc.	1,750,000	$7.42M	5.4%	N/A	4.272%
5/17/2024	Western Standard LLC	1,361,489	$9.87M	4.7%	+68.5%	4.978%
5/10/2024	Acadian Asset Management LLC	12,634	$91K	0.0%	N/A	0.046%
2/12/2024	AIGH Capital Management LLC	787,769	$3.95M	1.6%	-30.6%	3.180%
2/9/2024	Worth Venture Partners LLC	196,439	$0.98M	0.5%	-30.2%	0.793%
2/7/2024	Jump Financial LLC	39,757	$0.20M	0.0%	N/A	0.160%
11/15/2023	Worth Venture Partners LLC	281,280	$1.18M	0.7%	+76.6%	1.136%
11/15/2023	Adage Capital Partners GP L.L.C.	3,249,994	$13.68M	0.0%	+84.5%	13.126%
11/14/2023	Schonfeld Strategic Advisors LLC	153,930	$0.65M	0.0%	N/A	0.622%
11/13/2023	AIGH Capital Management LLC	1,135,252	$4.78M	2.3%	+77.7%	4.585%
11/9/2023	Citigroup Inc.	450,000	$1.89M	0.0%	+125.0%	1.817%
11/7/2023	Barclays PLC	371,276	$1.56M	0.0%	+100.0%	1.499%
11/1/2023	Simplex Trading LLC	14,128	$59K	0.0%	+1,889.9%	0.057%
7/27/2023	Virtu Financial LLC	32,171	$0.13M	0.0%	N/A	0.171%
5/11/2023	Knott David M Jr	160,000	$0.45M	0.2%	+6.7%	0.897%
2/16/2023	AIGH Capital Management LLC	652,174	$2.01M	0.7%	+363.7%	3.796%
2/15/2023	Nantahala Capital Management LLC	272,731	$4.19M	0.3%	N/A	1.587%
2/14/2023	EcoR1 Capital LLC	1,086,956	$3.35M	0.1%	N/A	6.327%
2/13/2023	Knott David M Jr	150,000	$0.46M	0.2%	N/A	0.873%
11/15/2022	Knoll Capital Management LLC	88,629	$0.27M	0.2%	-96.0%	1.490%
11/10/2022	Phoenix Holdings Ltd.	11,874	$35K	0.0%	-96.0%	0.200%
5/12/2022	AIGH Capital Management LLC	5,025,100	$1.58M	0.4%	+341.9%	3.410%
4/25/2022	Assenagon Asset Management S.A.	219,587	$69K	0.0%	-93.0%	0.149%
2/14/2022	Knoll Capital Management LLC	2,215,740	$0.65M	0.4%	-22.5%	2.174%
2/14/2022	Point72 Asset Management L.P.	3,200,000	$1.08M	0.0%	N/A	3.140%
2/14/2022	GSA Capital Partners LLP	788,085	$0.27M	0.0%	+2,254.9%	0.773%
2/10/2022	Acadian Asset Management LLC	236,681	$78K	0.0%	N/A	0.232%
2/10/2022	AIGH Capital Management LLC	1,137,274	$0.38M	0.1%	N/A	1.116%
2/9/2022	BNP Paribas Arbitrage SA	1,854,536	$0.63M	0.0%	+1,166,274.8%	1.820%
2/1/2022	Assenagon Asset Management S.A.	3,127,813	$1.05M	0.0%	+876.7%	3.069%
11/16/2021	ACT Capital L.L.C.	278,000	$0.31M	0.2%	N/A	0.275%
11/15/2021	Franklin Resources Inc.	325,000	$0.36M	0.0%	N/A	0.321%
11/15/2021	GSA Capital Partners LLP	33,466	$37K	0.0%	N/A	0.033%
11/9/2021	BlackRock Inc.	1,630,310	$1.83M	0.0%	-1.2%	1.611%
10/19/2021	Assenagon Asset Management S.A.	320,235	$0.36M	0.0%	+394.3%	0.316%
8/18/2021	Meitav Dash Investments Ltd.	122,000	$0.19M	0.0%	+24.5%	0.121%
8/17/2021	Millennium Management LLC	1,370,101	$2.14M	0.0%	N/A	1.353%
8/17/2021	Boothbay Fund Management LLC	24,764	$39K	0.0%	N/A	0.024%
8/16/2021	LMR Partners LLP	38,599	$60K	0.0%	N/A	0.038%
8/16/2021	Charles Schwab Investment Management Inc.	35,285	$56K	0.0%	-78.5%	0.035%
8/16/2021	State Street Corp	309,402	$0.48M	0.0%	-78.6%	0.306%
8/16/2021	Tibra Equities Europe Ltd	199,700	$0.31M	0.1%	N/A	0.197%
8/16/2021	Goldman Sachs Group Inc.	329,538	$0.52M	0.0%	+145.3%	0.326%
8/13/2021	Northern Trust Corp	137,346	$0.21M	0.0%	-78.1%	0.136%
8/13/2021	Kore Private Wealth LLC	77,459	$0.12M	0.0%	N/A	0.077%
8/13/2021	Qube Research & Technologies Ltd	22,572	$35K	0.0%	N/A	0.022%
8/13/2021	Geode Capital Management LLC	657,021	$1.02M	0.0%	-40.8%	0.649%
8/13/2021	Vanguard Group Inc.	3,727,536	$5.82M	0.0%	+6.6%	3.682%
8/12/2021	XTX Topco Ltd	76,941	$0.12M	0.0%	N/A	0.076%
8/12/2021	Dimensional Fund Advisors LP	177,147	$0.28M	0.0%	-18.4%	0.175%
8/12/2021	JPMorgan Chase & Co.	2,022,004	$3.15M	0.0%	+5.7%	1.997%
8/12/2021	Ergoteles LLC	179,300	$0.28M	0.0%	N/A	0.177%
8/11/2021	Bank of New York Mellon Corp	97,894	$0.15M	0.0%	-64.3%	0.097%
8/11/2021	BlackRock Inc.	1,649,387	$2.57M	0.0%	-66.9%	1.629%
8/11/2021	Deutsche Bank AG	400,558	$0.63M	0.0%	-8.8%	0.396%
8/10/2021	Principal Financial Group Inc.	22,746	$35K	0.0%	N/A	0.022%
8/5/2021	Platform Technology Partners	18,506	$29K	0.0%	N/A	0.018%
8/5/2021	Los Angeles Capital Management LLC	77,170	$0.12M	0.0%	-83.3%	0.076%
8/5/2021	Meitav Dash Investments Ltd.	122,000	$0.19M	0.0%	+24.5%	0.121%
8/4/2021	Russell Investments Group Ltd.	931,964	$1.45M	0.0%	+330.6%	0.921%
8/4/2021	Migdal Insurance & Financial Holdings Ltd.	112,859	$0.18M	0.0%	+21.2%	0.111%
5/20/2021	Axiom Investment Management LLC	32,500	$61K	0.0%	N/A	0.033%
5/19/2021	Virtu Financial LLC	56,225	$0.11M	0.0%	-52.4%	0.057%
5/19/2021	Squarepoint Ops LLC	13,302	$25K	0.0%	-78.6%	0.013%
5/18/2021	Morgan Stanley	529,753	$1M	0.0%	+193.1%	0.535%
5/18/2021	Jane Street Group LLC	62,782	$0.12M	0.0%	N/A	0.063%
5/17/2021	Nuveen Asset Management LLC	1,118,934	$2.10M	0.0%	+254.0%	1.130%
5/17/2021	Goldman Sachs Group Inc.	134,359	$0.25M	0.0%	+173.9%	0.136%
5/14/2021	Dimensional Fund Advisors LP	217,068	$0.41M	0.0%	-18.8%	0.219%
5/13/2021	QS Investors LLC	325,000	$0.61M	0.0%	+51.2%	0.328%
5/13/2021	Axiom Investment Management LLC	32,500	$61K	0.0%	N/A	0.033%
5/13/2021	Barclays PLC	50,598	$95K	0.0%	-37.7%	0.051%
5/13/2021	Renaissance Technologies LLC	522,282	$0.98M	0.0%	-60.5%	0.527%
5/12/2021	Northern Trust Corp	627,177	$1.18M	0.0%	-9.1%	0.633%
5/12/2021	Geode Capital Management LLC	1,109,189	$2.09M	0.0%	+5.1%	1.120%
5/12/2021	Financial Engines Advisors L.L.C.	21,445	$40K	0.0%	N/A	0.022%
5/12/2021	JPMorgan Chase & Co.	1,913,541	$3.60M	0.0%	+193.1%	1.932%
5/12/2021	Panagora Asset Management Inc.	19,812	$37K	0.0%	+657.6%	0.020%
5/11/2021	Boston Private Wealth LLC	19,500	$37K	0.0%	N/A	0.020%
5/11/2021	New York State Common Retirement Fund	28,300	$53K	0.0%	-48.1%	0.029%
5/11/2021	Vontobel Holding Ltd.	80,000	$0.15M	0.0%	N/A	0.081%
5/7/2021	BlackRock Inc.	4,980,925	$9.36M	0.0%	+21.8%	5.029%

Data available starting January 2016

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $5.70

$5.56

$5.79

50 Day Range

MA: $6.16

$5.63

$6.74

52 Week Range

Now: $5.70

$3.05

$9.01

Volume

210,374 shs

Average Volume

415,259 shs

Market Capitalization

$247.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Who are the company insiders with the largest holdings of Abeona Therapeutics?: Abeona Therapeutics' top insider shareholders include:
Vishwas Seshadri (CEO)
Joseph Walter Vazzano (CFO)
Brendan M O'malley (SVP)
Michael Amoroso (Director)
Christine Berni Silverstein (Director)
Leila Alland (Director)
Faith L Charles (Director)
Mark Alvino (Director)
Learn More about top insider investors at Abeona Therapeutics.
Who are the major institutional investors of Abeona Therapeutics?: Abeona Therapeutics' top institutional investors include:
Rosalind Advisors Inc. — 4.47%
Western Standard LLC — 3.92%
Walleye Capital LLC — 1.99%
Propel Bio Management LLC — 1.44%
Citigroup Inc. — 1.42%
Ikarian Capital LLC — 1.35%
Learn More about top institutional investors of Abeona Therapeutics stock.
Which institutional investors are selling Abeona Therapeutics stock?: In the last quarter, ABEO stock was sold by these institutional investors:
Propel Bio Management LLC
Ikarian Capital LLC
Walleye Capital LLC
Barclays PLC
Barclays PLC
State Street Corp
Which institutional investors are buying Abeona Therapeutics stock?: Within the previous quarter, ABEO stock was purchased by institutional investors including:
abrdn plc
Western Standard LLC
Geode Capital Management LLC
Rosalind Advisors Inc.
Citigroup Inc.
GSA Capital Partners LLP
XTX Topco Ltd
Charles Schwab Investment Management Inc.
Within the previous year, these company insiders have bought Abeona Therapeutics stock:
Vishwas Seshadri (CEO)
Joseph Walter Vazzano (CFO)
Brendan M O'malley (SVP)
Michael Amoroso (Director)
Christine Berni Silverstein (Director)
Learn More investors buying Abeona Therapeutics stock.